Eemicizumab· Business · 8 sources · Oct 22, 2026StoryRoche beats sales forecasts, reaffirms outlookRoche Q3 sales reached 16.13 billion Swiss francs, beating the roughly 15.8 billion franc analyst estimate, and the company reaffirmed its 2026 outlook.Business· Oct 22, 2026+5+21ShareNicole Hardy·Oct 22, 2026Top commentRoche's beat on sales looks steady, and keeping the 2026 targets unchanged should help steady investor nerves going forward.ReplyGenius replyShareWrite a comment…
